Neutrophilic dermatosis and hidradenitis suppurativa in patients with Behçet's disease: A neutrophilic disease in the spectrum of autoinflammatory syndromes

Semin Arthritis Rheum. 2023 Aug:61:152224. doi: 10.1016/j.semarthrit.2023.152224. Epub 2023 May 13.

Abstract

Background: Association of neutrophilic dermatosis (ND), hidradenitis suppurativa (HS) and Behçet's disease (BD) and shared efficacy of TNFα axis blockade suggests common physiopathology.

Objectives: To investigate the clinical features and therapeutic response of ND and HS associated with BD.

Methods: We identified 20 patients with ND or HS associated with BD among 1462 patients with BD.

Results: We analysed 20 (1.4%) patients diagnosed with ND or HS associated with BD: 13 HS, 6 pyoderma gangrenosum (PG), and 1 SAPHO. Our 6 PG cases over 1462 BD patients accounts for 400/100 000 prevalence. Thirteen had bipolar aphthosis, 6 vascular, 5 neurologic, and 4 ocular involvements. All PG occurred on limbs and had typical histology with constant dermal neutrophilic infiltrate. All HS had the classical axillary-mammary phenotype. Sixty-nine percent (69%) of HS were Hurley 1 stage. Treatment consisted mainly in colchicine (n = 20), glucocorticoids (n = 12), and anti-TNFα (n = 9). Interesting results with complete or partial responses were obtained with anti-TNFα (9 cases), ustekinumab (3 cases) and tocilizumab (1 case) to treat refractory ND or HS associated with BD.

Conclusion: PG seems overrepresented in patients with BD. Biotherapies such as anti-TNFα, ustekinumab and tocilizumab appear to be promising to treat refractory ND or HS associated with BD.

Keywords: Anti-TNFα; Behçet's disease; Hidradenitis suppurativa; Neutrophilic dermatosis; Pyoderma gangrenosum; SAPHO; Tocilizumab; Ustekinumab.

MeSH terms

  • Behcet Syndrome* / complications
  • Behcet Syndrome* / drug therapy
  • Hidradenitis Suppurativa* / complications
  • Hidradenitis Suppurativa* / drug therapy
  • Hidradenitis Suppurativa* / epidemiology
  • Humans
  • Pyoderma Gangrenosum* / complications
  • Pyoderma Gangrenosum* / drug therapy
  • Pyoderma Gangrenosum* / epidemiology
  • Ustekinumab / therapeutic use

Substances

  • Ustekinumab